fda warning letters bpc 157 2024 An advisory committee voted Thursday to remove compounding restrictions on four peptides despite little evidence the products are safe or effective for medical use. In a series of 8-6 votes (with FDA and FTC Issue 13

Kortekaas R, Leenders KL, van Oostrom JCH, Vaalburg W, Bart J, Willemsen ATM, et al

PMID 34186147 Mechanisms of subcutaneous absorption of therapeutic proteins

a 2025 literature review identified limited clinical evidence, including a retrospective study of 12 patients with knee pain and a Phase I trial in healthy volunteers whose results were not submitted

Here, we determine structures of cagrilintide bound to Gs-coupled, active, amylin receptors (AMY 1 R, AMY 2 R, AMY 3 R) and calcitonin receptor (CTR) and compare cagrilintide interactions and the dynamics of receptor complexes with previously reported structures of receptors bound to rat amylin, salmon calcitonin or recently developed amylin-based peptides